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ABSTRACT
Background: HBV is still a worldwide health problem. Annually about 0.5–1.2 million 
patients die of HBV-related diseases such as liver cirrhosis and hepatocellular carcino-
ma. Lamivudine (LAM) is the first nucleoside analog used in the treatment of chronic 
hepatitis B. As LAM has been clinically used for a long time, increasing clinical experi-
ence has been achieved showing that the resistance mutation rate is relatively high. 
Numerous studies have also focused on the predictive factors of long-term efficacy of 
LAM treatment.
Objectives: To determine the optimal cutoff values of baseline hepatitis B virus (HBV) 
DNA and alanine transaminase (ALT) levels as predictors for the long-term efficacy of 
LAM treatment in patients with chronic hepatitis B.
Patients and Methods: A total of 163 HBeAg-positive chronic hepatitis B patients receiv-
ing LAM treatment were recruited into the present study. Logistic regression analysis 
was performed to find out the independent predictors of 2-year on-treatment virologi-
cal response among the baseline parameters. The receiver operating characteristic 
(ROC) curve was used to evaluate the optimal cutoff values of these independent pre-
dictors. The accuracy of the prediction was assessed using the area under curve (AUC) 
and optimal cutoff values were determined through maximizing the Youden’s index.
Results: After 2 years of LAM treatment, undetectable HBV DNA was maintained in 114 
(69.9%) patients. LAM-related resistance mutation (YMDD mutation) was detected in 
45 (27.6%) patients. Logistic regression analysis indicated that the baseline ALT and 
HBV DNA levels were the independent predictors of the efficacy. ROC curve analysis 
suggested the integration parameter derived from the baseline ALT and HBV DNA lev-
els had the maximal predictive value for a 2-year on-treatment virological response. 
The optimal cutoff values of ALT and HBV DNA were 220 IU/L and 8.2 log10 copies/mL, 
respectively.
Conclusions: The incidence of LAM-resistant mutations in HBeAg-positive chronic hep-
atitis B patients may be significantly reduced and long-term efficacy improved when 
the baseline ALT was greater than 220 IU/L and HBV DNA was less than 8.2 log10 copies/
mL.
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Background
Nowadays, hepatitis B virus (HBV) infection is still 
a worldwide health problem. According to the statis-
tics of World Health Organization (WHO), there are ap-
proximately 400 million HBV carriers worldwide, 75% of 
whom reside in Asia and the Western Pacific. Moreover, 
annually about 0.5–1.2 million patients die of HBV-relat-
ed diseases such as liver cirrhosis and hepatocellular 
carcinoma (HCC) (1). For patients with chronic hepatitis 
B (CHB), antiviral therapy is the only treatment which 
can delay the progression of the disease and improve the 
long-term prognosis. Therefore, the anti-HBV therapy in-
cluding interferon-α and nucleos(t)ide analogs has been 
recommended by the guidelines for the management 
of CHB (2-6). Over the last decade, five nucleos(t)ide ana-
logs have been approved by Food and Drug Administra-
tion (FDA) for the treatment of CHB, which significantly 
improved the efficacy. However, the long-term efficacy 
of nucleos(t)ide analogs is not satisfactory due to drug 
resistance. Therefore, finding novel predictors for long-
term efficacy of anti-viral therapy has been the focus in 
research on CHB (7-12).
The recently revised clinical practice guidelines of 
European Association for the Study of the Liver (EASL) 
showed the pre-treatment predictive factors of HBeAg se-
roconversion were low viral load (HBV DNA below 107 IU/
mL or 7 log10 IU/mL), high serum ALT levels (above 3-fold 
ULN) and high activity scores on liver biopsy (5). How-
ever, the cutoff values of HBV DNA and ALT are inconsis-
tent in several studies (13-16). Of note, the thresholds of 
these parameters are frequently determined arbitrarily, 
according to expert advice or individual experience. The 
optimal cutoff value achieved from strictly statistical 
analysis has never been reported. Lamivudine (LAM) is 
the first nucleoside analog used in the treatment of CHB. 
In the early years, the mechanisms underlying LAM-re-
sistant mutations and their clinical consequences were 
not well recognized and LAM was once applied in all CHB 
patients in China (17, 18). Therefore, the resistance muta-
tion rate increased as high as 20% which affects the long-
term efficacy of LAM (19). As LAM has been clinically used 
for a long-time, increasing clinical experience has been 
achieved showing that the resistance mutation rate is 
relatively high, and thus numerous studies have focused 
on the predictive factors of long-term efficacy of LAM 
treatment (7). 
Objectives
The present clinical study was conducted to evaluate 
the predictive value of baseline HBV DNA and ALT levels 
in the long-term efficacy of LAM treatment using the re-
ceiver operating characteristic (ROC) curve analysis, and 
to determine the optimal cutoff values of these two pa-
rameters.
Patients and Methods
Ethics
The present study was an observational study and ethi-
cal issues involved privacy during data collection and 
preservation. The study was approved by the Ethics Com-
mittee of Beijing Ditan Hospital, Capital Medical Univer-
sity; all patients gave informed consents.
Patients and follow-up schedule
A total of 163 CHB patients receiving LAM treatment in 
Beijing Ditan Hospital, Capital Medical University from 
July 2003 to November 2006 were recruited into the pres-
ent study. All patients were HBeAg-positive. All patients 
met the following diagnostic criteria for HBeAg-positive 
CHB and had indications for LAM treatment (6):
patients were positive for serum HBsAg and HBeAg for 
longer than six months;
HBV DNA ≥ 105copies/mL;
ALT ≥ 2×ULN. All patients were given LAM, 100 mg daily 
and follow-up was performed once every 12 weeks. The se-
rum HBV DNA level, serological markers of HBV and liver 
biochemical parameters were monitored.
The primary end-points were as follows: detectable se-
rum HBV DNA by real time polymerase chain reaction 
(PCR, low limit of quantification, 500 copies/mL) at week 
24 or virological breakthrough (defined as detectable 
HBV DNA in patients who underwent undetectable HBV 
DNA within the first 24 weeks). The corresponding clini-
cal management was conducted for the patients with 
detectable serum HBV DNA at week 24. For patients who 
experienced virological breakthrough, drug resistance 
mutations were tested in addition to clinical manage-
ment. If the HBV DNA was maintained undetectable, the 
follow-up continued for two years.
Quantitative detection of serum HBV DNA
Real time PCR was used to quantitatively detect serum 
HBV DNA; to do so PG HBV FQ-PCR kit (PG Biotech, Shen-
zhen, China) was used. Because the detection range of 
this system was from 500 to 107 copies/mL, the serum was 
diluted 103-fold for re-examination when the HBV DNA 
was greater than 107 copies/mL.Hepat Mon. 2011;11(5):358-363
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Detection of HBV genotypes and reverse transcriptase 
gene mutations associated with LAM resistance
Direct sequencing was used on products of nested 
PCR to determine HBV genotypes and resistance muta-
tions within HBV reverse transcriptase gene. The prim-
ers used for nested PCR were as follows: P3 (5'-YCTCWSY-
CAYATCGTCAA-3'), AP3 (5'-GAGMCACAAAGGTTCCAC-3'), 
Xnp2 (5'-AGGCAGGATAGCCACATT-3'), and X Anp2 (5'-
GCACCGAACATGG AGARC-3'). After purification, dideoxy 
chain-termination method for sequencing DNA was used 
on products of nested PCR; the primer used was Xnp2. 
The synthesis of primers and DNA sequencing were 
performed in Shanghai (Sangon Biological Engineering 
Technology & Services Co., Ltd, Shanghai, China). DNA se-
quence analysis was conducted with molecular biologi-
cal software including DNAstar, ClustalX and GeneDoc.
Liver biochemistry and HBV serology
Liver biochemistry including ALT, total bilirubin, albu-
min, etc was determined every 12 weeks, using an auto-
mated chemical analyzer (Beckman Coulter, Fullerton, 
CA). HBV serological markers, including HBsAg, antibody 
to HBsAg, HBeAg, and antibody to HBeAg (anti-HBe), were 
determined every 12 weeks by a micro-particle enzyme 
immunoassay (Abbot Architect immunoassay system, 
Abbott Laboratories, Abbott Park, IL) with original re-
agents.
Definition of the on-treatment virological response at 
year 2
On-treatment virological response was considered 
when the HBV DNA was undetectable by real time PCR af-
ter 24-week of LAM treatment which was maintained for 
two years. Non-response to LAM treatment was consid-
ered when 1) HBV DNA was detectable after 24-week LAM 
therapy; or 2) HBV DNA was undetectable at week 24, but 
HBV DNA breakthrough was observed thereafter.
Statistical analysis
The demographics of patients with and without on-treat-
ment virological response were compared by Student’s t 
test for continuous data and x2 test for dichotomous vari-
ables. Cumulative rates including HBeAg seroconversion 
rate and LAM resistance mutation rate were analyzed by 
Kaplan-Meier procedure. Logistic regression analysis was 
used to screen independent predictors from the base-
line parameters for two-year on-treatment virological 
response. Receiver operating characteristic (ROC) curve 
and area under curve (AUC) were used to assess the opti-
mal cutoff values of the predictors through maximizing 
Youden’s index.
A p < 0.05 was considered statistically significant. A 95% 
confidence interval accompanied all estimates when it 
was appropriate. All analyses were performed by SPSS 
version 11.0 (SPSS Inc, Il, USA).
Results
Demographic characteristics and baseline parameters
Based on the presence of on-treatment virological re-
sponse, 163 patients were divided into two groups of 
“responders” and “non-responders.” The demographic 
characteristics were displayed in Table 1. Significant dif-
ference in baseline levels of ALT and HBV DNA was noted 
between responders and non-responders.
β a SE a p a RR a 95% CI a
ALT a (IU/L) 0.003 0.001 0.020 1.003 1.001 to 
1.006
HBV a DNA 
(log10 copies/mL)
 1.601 0.279 < 0.001 0.202 0.117 to 
0.349
Table 2. The Optimal logistic regression equation of baseline parameters in 
predicting the two-year on-treatment virological response to LAM treatment
a β: regression coefficient; SE: standard error; p: significance level; RR: rela-
tive risk; 95% CI: 95% confidence interval; ALT: Alanine aminotransferase; HBV: 
Hepatitis B virus
AUC a SE a P b 95% CI a for AUC a
ALT a 0.689 0.045 <0.001 0.600, 0.777
HBV a DNA 0.848 0.033 <0.001 0.783, 0.912
ALT and HBV 
DNA c
0.869 0.030 <0.001 0.811, 0.927
Table 3. AUC of the baseline ALT and HBV DNA in predicting the two-year on-
treatment virological response to LAM treatment
a AUC: Area under the curve; SE: standard error; CI: confidence interval; ALT: 
Alanine aminotransferase; HBV: Hepatitis B virus
b P: Statistical significance implies that the corresponding AUC was signifi-
cantly different from 0.5
c Integration parameter derived from the optimal logistic regression equa-
tion: 0.003*ALT(IU/L)-1.601*HBV DNA (log10 copies/mL)
Integration Parameter = 0.003 × ALT (IU/L) - 1.601 × HBV DNA (log 10 copies/ml)
 
Responders 
(No. = 114)
Non-responders 
(No. = 49)
p-value
Sex
Male
Female
0.997
107 46
7 3
Age (years) 31.3 (11.6) 32.0 (10.7) 0.725
ALT a (IU/L) 329.7 (298.5) 183.2 (146.4) < 0.001
Albumin (g/L) 40.9 (5.9) 42.7 (5.9) 0.098
Bilirubin (μmol/L) 35.6 (50.9) 23.8 (36.9) 0.078
HBV b DNA 
(log10 copies/mL)
7.4 (0.9) 8.7 (0.8) < 0.001
Genotype 0.74
  B 32 15
  C 82 34
Table 1. Demographic characteristics and baseline parameters (Continuous 
variables are expressed as medians (range))
a ALT: Alanine aminotransferase
b HBV: Hepatitis B virusHepat Mon. 2011;11(5):358-363
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Efficacy and LAM resistance mutation rate after two 
years of LAM treatment
After two years of LAM treatment, HBV DNA was main-
tained undetectable in 114 (69.9%) patients which sug-
gested on-treatment virological response. Furthermore, 
74 (45.4%) patients had HBeAg loss and 38 (23.3%) had 
HBeAg seroconversion. HBV DNA breakthrough was ob-
served in 49 (30.1%) patients in the two-year LAM therapy, 
of whom 45 (27.6%) had LAM-related resistance (YMDD) 
mutation.
Optimal logistic regression equation in screening base-
line parameters for the prediction of two-year on-treat-
ment virological response
The baseline parameters with a p < 0.1 in the univariate 
analysis (including ALT, albumin, bilirubin, HBV DNA) 
served as candidate independent variables; the two-year 
on-treatment virological response was considered as the 
outcome (dependent) variable to be used in multivariate 
logistic regression analysis with forward variable selec-
tion technique (Table 2). Among the two variables, the 
relative risk (RR) of baseline ALT was 1.003 (95% CI: 1.001–
1.006), suggesting the greater the ALT, the higher the pos-
sibility of on-treatment virological response achieved by 
patients. On the contrary, the RR of baseline HBV DNA 
was 0.202 (95% CI: 0.117–0.349), suggesting patients with 
lower-level HBV DNA are more likely to achieve on-treat-
ment virological response.
Determination of predictive values of baseline levels 
of ALT and HBV DNA in prediction of two-year on-treat-
ment virological response with ROC curve
The baseline ALT, HBV DNA and integration parameter 
derived from the optimal logistic regression equation 
above were used as the predictors for two-year on-treat-
ment virological response to construct an ROC curve 
(Figure 1). Among these parameters, the integration pa-
rameter had the largest AUC of 0.869 followed by HBV 
DNA (AUC = 0.848). The AUCs of these two parameters 
were > 0.7 suggesting an acceptable predictive value. The 
AUC of ALT was only 0.689 indicating a poor predictive 
value (Table 3).
Optimal cutoff values of baseline levels of ALT and HBV 
DNA in predicting two-year on-treatment virological 
response
Based on the maximization of Youden’s index, the opti-
mal cutoff values of baseline levels of ALT and HBV DNA 
were 220 IU/L and 8.2 log10 copies/mL, respectively, with 
the corresponding Youden’s index of 0.31 and 0.56, re-
spectively. If the optimal cutoff values were substituted 
into the optimal logistic regression equation, Youden’s 
index of the integration parameter was 0.39. The corre-
sponding test statistics are listed in Table 4. The possibil-
ity of two-year on-treatment virological response was 
84.7% when the baseline level of ALT was > 220 IU/L. If the 
baseline level of HBV DNA was < 8.2 log10 copies/mL, the 
patients had a probability of 87.3% to achieve a two-year 
on-treatment virological response. The two-year sus-
tained virological response rate was increased to 95.5% 
when the ALT was > 220 IU/L and HBV DNA < 8.2 log10 cop-
ies/mL.
Discussion
Increasing studies confirmed that resistance mutation 
of reverse transcriptase domain of HBV DNA polymerase 
is the main cause of compromised long-term efficacy 
of nucleos(t)ide analogs in CHB patients (20, 21). There-
fore, predicting the long-term efficacy of nucleos(t)ide 
analogs is equivalent to predicting presence of a resis-
tance mutation. Among the five nucleos(t)ide analogs 
used in the treatment of CHB, entecavir has extremely 
low resistance mutation rate and the five-year resistance 
mutation rate is only 1.2% when the patients are treated 
initially with entecavir (22). Tenofovir disoproxil fumar-
ate is a new drug approved by FDA to be used in the treat-
ment of CHB, and no studies have reported the long term 
efficacy as well as resistance mutation rate (23). However, 
LAM, adefovir dipivoxil and telbivudine have relatively 
ALT HBV DNA ALT and HBV DNA
Optimal cutoff value 220 IU/L 8.2 log10 copies/mL ALT = 220 IU/L and HBV DNA = 8.2 log10 copies/mL
Sensitivity 53.5% (44.4%–62.7%) 84.2% (77.5%–90.9%) 45.6% (36.4%–54.8%)
Specificity 77.6% (65.9%–89.2%) 71.4% (58.8%–84.1%) 93.8% (87.2%–100%)
Likelihood ratio
Positive
Negative
2.38 (1.37–4.12)
0.60 (0.47–0.77)
2.95 (1.88–4.62)
0.22 (0.14–0.35)
7.45 (2.44–22.71)
0.58 (0.48–0.70)
Predictive value
Positive
Negative
84.7% (76.4%–93.0%)
41.8% (31.6%–51.9%)
  87.3% (81.0%–93.5%)
  66.0% (53.3%–78.8%)
95.5% (88.5%–100%)
42.6% (33.3%–52.0%)
Table 4. Cutoff values of the baseline levels of ALT and HBV DNA in predicting the two-year on-treatment virological response to LAM treatment
Note: The values in parentheses represent the 95% confidence intervalsHepat Mon. 2011;11(5):358-363
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high resistance mutation rates and the two-year resis-
tance mutation rates are 38%, 3% and 17%, respectively (5, 
24). Therefore, studies on the predictive factors of long-
term efficacy of nucleos(t)ide analogs have paid more at-
tention to these three analogs. The predictive factors in 
guidelines for the management of CHB patients and ex-
pert consensus mainly include the baseline levels of ALT 
and HBV DNA and decreased level of HBV DNA in the early 
treatment (5, 25, 26).
Few studies have been conducted to quantitatively de-
termine the optimal cutoff values of these predictive fac-
tors. Yuen, et al. (27) investigated the predictive factors 
of five-year efficacy of LAM treatment in 74 CHB patients 
positive for HBeAg. They used the ROC curve to determine 
the optimal time and HBV DNA level during an early 
treatment period for the prediction of the response. They 
drew the conclusions that HBV DNA levels at the 4th week 
of LAM therapy could predict the five-year ideal response, 
and that 4 log10 copies/mL was the optimal cutoff value of 
HBV DNA level at the 4th week of LAM treatment. 
We found a maintained HBV DNA response rate of 69.9% 
and a resistance mutation rate 27.6% after a two-year LAM 
therapy which was consistent with previous studies. 
Univariate and multivariate analyses identified the in-
dependent predictive factors (baseline ALT and HBV DNA 
levels) of long-term efficacy of LAM treatment which was 
also consistent with previously reported. The ROC curve 
analysis indicated that the integration parameter de-
rived from the baseline levels of ALT and HBV DNA had 
the maximal predictive value for a two-year on-treatment 
virological response, with an AUC of 0.869. The cutoff val-
ues of baseline levels of ALT and HBV DNA, which were de-
termined by Youden’s index maximization, were 220 IU/L 
and 8.2 log10 copies/mL, respectively. For the CHB patients 
of our study, there was a probability of 95.5% to achieve 
on-treatment virological response after two-year LAM 
treatment when the baseline ALT was > 220 IU/L and HBV 
DNA was < 8.2 log10 copies/mL. Therefore, favorable long-
term efficacy of LAM therapy may be achieved among 
CHB patients meeting the said criteria. Other drugs, es-
pecially those with a low resistance mutation rate, such 
as entecavir and tenofovir disoproxil fumarate, should 
be considered for patients who do not fulfill the criteria 
above (28, 29).
These optimal cutoff values were come from a long-
term follow-up study in which CHB patients receiving 
LAM treatment. Whether these cutoff values can be ap-
plied to the treatment of CHB patients undergoing other 
nucleos(t)ide analogs therapy needs to be studied. Fur-
thermore, only few large-scale studies have been con-
ducted to explore the long-term efficacy of LAM treat-
ment in HBeAg-negative CHB patients. These patients 
were also excluded from the present study. Therefore, the 
predictive factors of long-term efficacy and the optimal 
cutoff values in HBeAg-negative CHB patients should be 
further studied.
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